ANP like many other Biotech has been sold down. It's not unique, and some companies have countered the trend, but in general, ANP is experiencing what other companies are experiencing, it doesn't seem reflective on one Board or CEO in particular.
The market is a wild untamable beast, many don't understand it and will interpret things subjectively, what can you do, some people just can't be objective.
For General Information, page-243
-
- There are more pages in this discussion • 3,284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.002(2.50%) |
Mkt cap ! $70.32M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.8¢ | 7.5¢ | $32.58K | 429.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 253224 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 253231 | 2 |
View Market Depth
| Last trade - 14.56pm 22/07/2024 (20 minute delay) ? |
| PER (ASX) Chart |